Clinical Trials Logo

NSCLC clinical trials

View clinical trials related to NSCLC.

Filter by:
  • Enrolling by invitation  
  • Page 1

NCT ID: NCT05710133 Enrolling by invitation - NSCLC Clinical Trials

The Food-effect on Alectinib Pharmacokinetics

Start date: February 1, 2024
Phase: N/A
Study type: Interventional

The goal of this food-effect study on Alectinib pharmacokinetics is to learn about the food effect of alectinib. The main question aims to answer is: • To determine the food-effect of a standardized Dutch breakfast on the pharmacokinetics of oral alectinib (Alecensa®), especially Peak Plasma Concentration (Cmax), Area under the plasma concentration versus time curve (AUC) and relative bioavailability, at steady state using a stable isotopically labelled microtracer approach. Participants will take alectinib-d6 (microtracer) with and without food on different days.

NCT ID: NCT03801200 Enrolling by invitation - NSCLC Clinical Trials

Apatinib Combined With Radiotherapy in Patient With BM From Drive Gene Negative NSCLC

Start date: September 10, 2020
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of concurrent radiotherapy with Apatinib in patients with Brain Metastases from drive gene wide-type Non-small-cell Lung Cancer (NSCLC).

NCT ID: NCT02283021 Enrolling by invitation - NSCLC Clinical Trials

Expression and Sequence of Calcium Channels in Non-small Cell Lung Carcinoma (NSCLC)

Start date: January 2015
Phase: N/A
Study type: Observational

Calcium is an extremely important ion used in our body for many processes. One of its tasks is to control gene expression. Cells intake calcium from their surroundings though special calcium channels located on the surface membranes of the cells. The great many studies on such calcium channels were performed on excitable cells such as muscle, heart or neuronal cells, where the calcium ions are controlled by voltage. Surprisingly, not much is known about the identity of calcium subunits in non-excitable cells like epithelial cells (which compose most of the connective tissue in the body), liver cells, lung cells, immune system cells, etc. Recently, the investigators have shown that calcium channels from muscles are, in fact, expressed in T cells of the immune system, where they are used for proliferation. The investigators postulated that probably other cell types, especially cancerous cell types, might be using these subunits similarly. The aim of this study is to determine the identity and sequence of calcium subunits expressed in non-small cell Lung Carcinoma (NSCLC), which accounts for 80% of the worldwide lung cancer deaths.